Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome
Martina Sanlorenzo(University of California, San Francisco), Pietro Quaglino(Department of Medical Sciences), Maria Teresa Fierro(University of Turin), Mauro Novelli(University of Turin), Ornella Cervetti(University of Turin), Simona Osella‐Abate, Federica Marenco(University Dermatology), Simone Ribero, Maria Grazia Bernengo(University of Turin), Tiziana Nardò(University of Turin)
Cited by 19
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas
|Journal of the American Academy of Dermatology|2002|493
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452